Arch Venture Corp

Latest statistics and disclosures from ARCH Venture Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are RVMD, VERV, ERAS, DNLI, GOSS, and represent 97.74% of ARCH Venture Management's stock portfolio.
  • Added to shares of these 1 stock: RVMD (+$93M).
  • Started 1 new stock position in RVMD.
  • Reduced shares in these 2 stocks: Eqrx (-$81M), DNLI (-$6.7M).
  • Sold out of its position in Eqrx.
  • ARCH Venture Management was a net buyer of stock by $5.4M.
  • ARCH Venture Management has $164M in assets under management (AUM), dropping by 6.20%.
  • Central Index Key (CIK): 0001274403

Tip: Access up to 7 years of quarterly data

Positions held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for ARCH Venture Management

ARCH Venture Management holds 7 positions in its portfolio as reported in the December 2023 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Revolution Medicines (RVMD) 56.7 $93M NEW 3.2M 28.68
 View chart
Verve Therapeutics (VERV) 17.1 $28M 2.0M 13.94
 View chart
Erasca (ERAS) 14.4 $24M 11M 2.13
 View chart
Denali Therapeutics (DNLI) 5.0 $8.2M -45% 381k 21.46
 View chart
Gossamer Bio (GOSS) 4.5 $7.4M 8.1M 0.91
 View chart
Unity Biotechnology (UBX) 1.2 $1.9M 1.0M 1.93
 View chart
Singular Genomics Systems In (OMIC) 1.1 $1.7M 3.8M 0.46
 View chart

Past Filings by ARCH Venture Management

SEC 13F filings are viewable for ARCH Venture Management going back to 2018

View all past filings